White arrows indicate the formation of neuro-spheres as previously described [21, 22]. D: Representative images of immunofluorescence detection of FANCD2 nuclear foci in two independently derived primary glioma cultures as described in Figure 2D . Shown is FANCD2 staining alone or merged with DAPI staining to allow visualisation of FANCD2 foci within the nucleus. The relatively few red dots that reside outside the nucleus represent non-specific antibody staining and are common with this application.
Supplementary
: A: Quantification of nuclear FANCD2 foci in U87 and U138 cells treated with the indicated FAPi and BCNU (DMSO serves as a negative control). Means were calculated from at least three independent experiments with error bars representing the standard deviation of the means. B: MTT BCNU cytotoxicity assays for U87 and U138 cells pre-treated with either DMSO or the indicated FAPi. Data shown was derived from at least three independent experiments and solid, dashed lines and error bars are as described in Figure 3A . C: MTT Temozolomide cytotoxicity assays for an additional primary glioma culture derived from surplus clinical material collected at the neuro-oncology unit at Sheffield's Royal Hallamshire Hospital. Solid, dashed lines and error bars are as described in Figure 3A . D: Western blot of T98G, U87 and U138 cells showing MGMT expression and tubulin (loading control). E: Western blot showing FANCD2 expression and activation (Ub-FANCD2) following Temozolomide treatment in an additional stable U87 cell line expressing FANCD2 directed shRNA (different target sequence to that used to generate the cell line shown in Figure 4) . F: MTT Temozolomide cytotoxicity curves for the additional stable FANCD2-depleted (shRNA) U87 cell clone shown in panel E. Cells were pre-treated with either DMSO (solid line) or curcumin (dashed line) prior to TMZ treatment at the indicated dose. Data shown was derived from at least three independent experiments error bars representing the standard deviation of the means.
